Results 61 to 70 of about 8,073 (209)
British Journal of Pharmacology, EarlyView.Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley +1 more source
Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides As Potent and Selective PDE5 Inhibitors [PDF]
, 2000 A previous report from these laboratories identified the N-3-benzylimidazoquinazolinone nucleus as a more selective PDE5 inhibitor template compared to the pyrazolopyrimidine of sildenafil.
Sun, Zhong +7 more
core +1 more source
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
Frontiers in Oncology, 2021 The use of already-approved drugs to treat new or alternative diseases has proved to be beneficial in medicine, because it reduces both drug development costs and timelines.
Marian Cruz-Burgos +8 more
doaj +1 more source
Pulmonary Circulation, Volume 16, Issue 3, September 2026.ABSTRACT Selection of therapy for pulmonary arterial hypertension (PAH) requires tradeoffs among disease severity, therapeutic benefit, adverse effects, treatment burden, quality of life, and patient values. Although professional societies endorse shared decision‐making (SDM) in this context, empirical data describing SDM in PAH are limited.
Paresh C. Giri +7 more
wiley +1 more source
Furoyl and Benzofuroyl Pyrroloquinolones as Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction [PDF]
, 2016 Synthesis of furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors was reported. Their in vitro potencies in inhibiting PDE5 and selectivity in inhibiting other PDE isozymes (PDE1−4 and PDE6) were evaluated.
James C. Lanter (1702399) +13 more
core +1 more source
Substituted Pyrazolopyridopyridazines as Orally Bioavailable Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile Dysfunction [PDF]
, 2016 Novel pyrazolopyridopyridazine derivatives have been prepared as potent and selective PDE5 inhibitors. Compound 6 has been identified as a more potent and selective PDE5 inhibitor than sildenafil (1). It is as efficacious as sildenafil in in vitro and in
Bruce Beyer (3016440) +16 more
core +3 more sources
Pulmonary Circulation, Volume 16, Issue 3, September 2026.ABSTRACT Pulmonary arterial hypertension (PAH) is a rare, progressive disease with high morbidity and mortality. Real‐world data from Israel are scarce. This study aimed to estimate the incidence, describe treatment patterns, and quantify healthcare utilization and costs associated with PAH in Israel.
Yaki Saciuk +12 more
wiley +1 more source
Revisiting Controversial Areas in the Management of Premature Ejaculation
Trends in Urology &Men's Health, Volume 17, Issue 4, August 2026.ABSTRACT The cause of premature ejaculation (PE) is often multifactorial in nature, and effective management of PE is complex and should involve multimodal approaches. This narrative review examines the ongoing controversies surrounding key areas in the diagnosis and treatment of PE with an emphasis on future research directions to align clinical care ...
Dong Sup Lee +6 more
wiley +1 more source
The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA
The Journal of Sexual Medicine, 2013 ABSTRACT Introduction TPN729MA is a newly developed phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction, which offers potential for greater selectivity and longer duration of action than PDE5i in current clinical use ...
Zhen, Wang +11 more
openaire +2 more sources
PLoS ONE, 2019 The natural product icariin inhibits human phosphodiesterase-5 (PDE5) and represents a unique pharmacophore for treating erectile dysfunction, pulmonary hypertension, and other diseases.
Yasmin Chau +3 more
doaj +1 more source